Abdominal aortic aneurysms (AAAs) continue to be a leading cause of death, with increasing incidence and prevalence. Endovascular aneurysm repair (EVAR) now represents the most common method of AAA repair in the United States. Ongoing improvements in endovascular stent-graft technology have occurred since the first published report of EVAR in 1991. These improvements have led to multiple US Food and Drug Administration-approved devices, streamlined operative techniques, and extended applicability of EVAR. Despite these facts, basic anatomic considerations still eliminate many patients from being offered EVAR. Distinct advantages of EVAR over open repair have been demonstrated, including a less invasive operative exposure, decreased transfusion requirements, shortened intensive care unit and hospital stay, and decreased perioperative mortality. It is our opinion that in 2009, anatomically suitable patients should be offered EVAR as first-line therapy, except for the less common scenario of the young and fit patient, for which open repair should be strongly considered. Use of EVAR for ruptured AAAs also has shown promise, yielding survival results commensurate with the best single-center results with open repair for rupture. However, questions remain regarding the long-term efficacy of EVAR in preventing aneurysm-related death for all patients treated with this technique. As device improvements and technical advances continue, it is reasonable to expect that long-term results will improve as well. Furthermore, the advent of fenestrated and multi-branch endograft technology is expanding indications, and will continue to enlarge the percentage of patients who will be considered acceptable candidates for EVAR. Lastly, randomized clinical trials are under way to determine whether the generally accepted threshold of 5.5 cm for elective open AAA repair should be decreased in patients who are candidates for EVAR. Until further data emerge, standard guidelines for elective aneurysm repair should remain the norm.